Rotsinger Joseph E, Celada Lindsay J, Polosukhin Vasiliy V, Atkinson James B, Drake Wonder P
1 Divisions of Infectious Diseases and.
2 Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, and.
Am J Respir Cell Mol Biol. 2016 Jul;55(1):128-34. doi: 10.1165/rcmb.2015-0212OC.
Sarcoidosis is a granulomatous disease of unknown cause. Prior molecular and immunologic studies have confirmed the presence of mycobacterial virulence factors, such as catalase peroxidase and superoxide dismutase A, within sarcoidosis granulomas. Molecular analysis of granulomas can identify targets of known antibiotics classes. Currently, major antibiotics are directed against DNA synthesis, protein synthesis, and cell wall formation. We conducted molecular analysis of 40 sarcoidosis diagnostic specimens and compared them with 33 disease control specimens for the presence of mycobacterial genes that encode antibiotic targets. We assessed for genes involved in DNA synthesis (DNA gyrase A [gyrA] and DNA gyrase B), protein synthesis (RNA polymerase subunit β), cell wall synthesis (embCAB operon and enoyl reductase), and catalase peroxidase. Immunohistochemical analysis was conducted to investigate the locale of mycobacterial genes such as gyrA within 12 sarcoidosis specimens and 12 disease controls. Mycobacterial DNA was detected in 33 of 39 sarcoidosis specimens by quantitative real-time polymerase chain reaction compared with 2 of 30 disease control specimens (P < 0.001, two-tailed Fisher's test). Twenty of 39 were positive for three or more mycobacterial genes, compared with 1 of 30 control specimens (P < 0.001, two-tailed Fisher's test). Immunohistochemistry analysis localized mycobacterial gyrA nucleic acids to sites of granuloma formation in 9 of 12 sarcoidosis specimens compared with 1 of 12 disease controls (P < 0.01). Microbial genes encoding enzymes that can be targeted by currently available antimycobacterial antibiotics are present in sarcoidosis specimens and localize to sites of granulomatous inflammation. Use of antimicrobials directed against target enzymes may be an innovative treatment alternative.
结节病是一种病因不明的肉芽肿性疾病。先前的分子和免疫学研究已证实在结节病肉芽肿内存在分枝杆菌毒力因子,如过氧化氢酶过氧化物酶和超氧化物歧化酶A。对肉芽肿进行分子分析可以识别已知抗生素类别的靶点。目前,主要抗生素针对DNA合成、蛋白质合成和细胞壁形成。我们对40份结节病诊断标本进行了分子分析,并将其与33份疾病对照标本比较,以检测编码抗生素靶点的分枝杆菌基因的存在情况。我们评估了参与DNA合成(DNA解旋酶A[gyrA]和DNA解旋酶B)、蛋白质合成(RNA聚合酶亚基β)、细胞壁合成(embCAB操纵子和烯酰还原酶)以及过氧化氢酶过氧化物酶的基因。进行免疫组织化学分析以研究12份结节病标本和12份疾病对照中分枝杆菌基因如gyrA的定位。通过定量实时聚合酶链反应在39份结节病标本中的33份中检测到分枝杆菌DNA,相比之下,30份疾病对照标本中有2份检测到(P < 0.001,双侧Fisher检验)。39份中有20份对三种或更多分枝杆菌基因呈阳性,相比之下,30份对照标本中有1份(P < 0.001,双侧Fisher检验)。免疫组织化学分析将分枝杆菌gyrA核酸定位到12份结节病标本中的9份肉芽肿形成部位,相比之下,12份疾病对照中有1份(P < 0.01)。结节病标本中存在可被现有抗分枝杆菌抗生素靶向的编码酶的微生物基因,并且定位于肉芽肿性炎症部位。使用针对靶酶的抗菌药物可能是一种创新的治疗选择。